Answers are grounded in this paper and cite their sources.
In ‘Gene copy number variation and pediatric mental health/neurodevelopment in a general population’ the authors, led by Scherer, describe a set of analyses focused on enrichment of copy number variation and its relationship to mental health phenotypes in population/community sample data [cite paper once available]. The finding of significant associations between clinically significant and/or susceptibility CNVs and several neurobehavioral phenotypes joins a growing number of studies that identify genetic contributions to mental health. The work also extends prior results by identifying that genetic contributions to child and adolescent mental health can even be seen at the population level, where most categorical mental health diagnoses are infrequent or frankly rare. In the discussion, the authors also raise the possibility that CNV enrichments for some conditions or traits may be of a sufficient size, which, if combined with other information, may provide value in identifying neurobehavioral problems. If true, this has great potential to enhance, and increase the objectivity of the clinical diagnostic process and could lead to earlier, tailored intervention strategies. However, it is not yet clear how often and for what types of conditions or traits these CNV–behavior associations will have clinical value. Potentially, as datasets get orders of magnitude larger and bioinformatic methods get more sophisticated, many more clinically-useful associations will be found, including patterns useful for early detection as well as those for patient stratification and intervention tailoring. Clearly, the present findings are promising and additional investment into discovering associations between structural variation and mental health conditions seems worth further advancing. Beyond identifying the relevance of CNVs to pediatric neurobehavioral conditions and traits, the paper also serves as a demonstration of the potential power of combining genotypic information with broad phenotypic dimensions—not just diagnostic categories—relevant to development and child and adolescent functioning. This demonstration points toward a future where very large and well-curated datasets permit making real progress in linking genes to behavior. However, I suspect that, to realize this future, it will require building data structures more thoughtfully, and potentially with much greater expense, than has been done previously. It seems unrealistic to hope that our understanding of neurobehavior will ever be sufficient without very large databases (>100k samples) that include collection of multiomic, neural systems, cognitive/affective AND behavioral measurements from all participants. Without multiple levels of information, filling the gaps between genes and behavior, it will not be possible to build more complete models of the underlying molecular and neural substrates of complex behavior patterns and associated neurobehavioral pathology. Luckily, this seems increasingly possible. Efforts such as the NIH All of Us project (https://allofus.nih.gov/) are providing a template for future cohort building with more detailed phenotypic data collection. Multiomic data remain very expensive, but sequencing, data capture, and storage costs continue to decrease rapidly. Further, there are emerging technologies that facilitate reliable collection of neural systems information, including relatively inexpensive ambulatory wearables with EEG and other sensors (see https://dreem.com/clinicaltrials for an example) and newly-developed ambulatory MEG (1) that can even be obtained in many young and impaired children. Digital phenotyping methods for capturing cognitive, affective and behavioral information are also proliferating rapidly, often at very low cost and frequently permitting temporally-sensitive and ecologically valid measurement (2). The type of big data collections envisioned will not only require dense molecular and neural and physiological systems data collection, but should also pay careful attention to the longitudinal collection of specific neurobehavior constructs. In the present paper, several associations were seen with inattention and hyperactivity, distinct aspects of ADHD, as well as the cognitive constructs of response inhibition and response variability. This greatly extends the specificity of prior work and suggests that there are likely behavioral sub-domains and transdiagnostic traits that are influenced by genetic variation. These sub-domains and traits are more likely to have value in developing a more complete model of the pathway from genes to neural systems to behavior. Yet, the present work only scratches the surface. Most of the findings are most relevant to ADHD, not surprising due to these behaviors being of higher prevalence in the population, and the study included only a small number of potential cognitive and affective dimensions relevant to developmental neuropsychiatric conditions. There are numerous sub-domains and transdiagnostic constructs relevant to developmental psychopathology (3,4). Including a broader array of neurobehavioral domains in the population databases of the future will greatly increase the information available for building models of normal and pathological development, especially if the data are captured longitudinally at developmentally-relevant timepoints. The authors should be commended for pointing the field toward a future with enormous potential to expand our knowledge of the development of neurobehavior and child mental health beyond simple gene–disease associations. However, this future will only be realized with substantial investment in building new large and deep datasets while simultaneously growing the next generation of researchers with the ability to lead multi-disciplinary teams. These teams should include representation of the levels of analysis from genes to behavior but also need to include bioinformaticians and statisticians with expertise in building models of behavior from dense multi-level array data and clinical and dissemination science researchers who can translate new discoveries into clinically-actionable findings that improve public health.
No takes yet. Share an insight, caveat, or question.
Thomas Frazier (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: